| Message: | Product name Testosterone Base
Other name Testoviron; Oreton; Testex; Testoderm; Testred; Virilon; Testolent
CAS register number 58-22-0
EINECS 200-370-5
Molecular formula C19H28O2
Molecular weight 288.42
Assay 98%
Appearance White crystalline powder
Usage can be used as pharmaceutical material
Purpose: to promote the development of male genitalia and maintain their normal function, for disease-free testosterone replacement therapy, male menopause syndrome, impotence and other diseases Treatment, but also for women of functional uterine bleeding, dysmenorrhea, menorrhagia, aplastic anemia embolism. Usually used and its propionate ester derivatives of benzoic acid.
Data presented on June 17, 2013, at the Endocrine Society's 95th Annual Meeting offered positive results regarding the use of testosterone to improve pain tolerance. Narcotic analgesics often lead to lower than normal testosterone levels in men, thus adding to their perceived pain, as well as contributing to symptoms like irritability and depression. The patents for two well-known and efficacious testosterone treatments.
Striant and Testoderm, have patent expirations of August 23, 2019 and November 10, 2019, respectively. The National Institutes of Health states that approximately 5 million American men do not produce enough of the hormone testosterone. Axiron is a highly profitable testosterone replacement therapy, with a patent expiration of February 19, 2017. The testosterone replacement Axiron generated over $48 million dollars in profit in 2011.
Coined “The Wittert Study”, after Gary Wittert who is the leader of this study, this novel study is banking on being the first of many to address the worldwide epidemic of type 2 diabetes using testosterone treatment as a preventative. The International Diabetes Federation has stated that the cost to treat type 2 diabetes worldwide now hovers at 471 billion dollars. |
my account
